CyclosetTM for the Treatment of Type 2 Diabetes
Scientists at VeroScience have invented and developed a novel approach to the treatment of Type 2 Diabetes that involves the timed daily administration of a quick release formulation of a central acting dopamine agonist, bromocriptine.
Decades of work investigating animals in the wild that undergo marked annual cycles of metabolism revealed that seasonal shifts from the obese, insulin resistant condition to the lean, insulin sensitive state are driven by shifts in the circadian phase relations of specific hypothalamic neurotransmitter levels.
By mimicking this neurophysiological shift by pharmacological interventions it is possible to effectuate the predicted shift in metabolism. Similar approaches in a variety of genetic and diet-induced animal models of Type 2 Diabetes have produced similar results.
Available evidence indicates that the therapy acts centrally to reset hypothalamic centers regulating postprandial insulin-mediated glucose and lipid metabolism to thereby reduce postprandial hyperglycemia and hyperlipidemia.
Cycloset is a first-in-class, central acting agent for the treatment of Type 2 Diabetes that has the potential of combination therapy with all other existing agents for Type 2 Diabetes. The U.S. Food and Drug Administration has issued an approvable letter for the Cycloset NDA for the treatment of Type 2 Diabetes and clinical studies with the drug required to address the approvable letter are now near complete.